Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Christine M. Ho,¹ Philip L. McCarthy,¹ Paul K. Wallace,² Yali Zhang,¹ Ahmad Fora,¹ Patrick Mellors,¹ Joseph D. Tario,² Benjamin L. S. McCarthy,¹ George L. Chen,¹ Sarah A. Holstein,³ Sophia R. Balderman,¹ Xuefang Cao,⁴ Bruno Paiva,⁵ and Theresa Hahn¹

¹Department of Medicine and ²Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Buffalo, NY; ³Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE; ⁴Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY; and ⁵Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

Key Points

- Specific immune phenotypes were predictive of long-term survival for MM patients undergoing transplantation.
- MRD status and use of maintenance therapy were associated with unique immune profiles predictive of outcome.

Multiple therapeutic options exist for multiple myeloma (MM), including autologous hematopoietic stem cell transplantation (AHSCT). Measurement of minimal residual disease (MRD) and immune reconstitution is rapidly becoming an integral part of the care of MM patients. We investigated comprehensive immune profiling (IP) associated with progressionfree survival (PFS) and overall survival (OS). From August 2007 to January 2014, 101 consecutive MM patients underwent peripheral blood IP and marrow MRD testing before and approximately 100 days after AHSCT. Higher pre-AHSCT CD19⁺ B-cell counts correlated with improved 2-year PFS (83% [highest quartile] vs 53% [lowest quartile]; P = .01) and OS (93% [highest quartile] vs 63% [lowest quartile]; P = .0003). This effect was seen primarily in patients with MRD-positive marrow tests. Higher γδ T-cell counts post-AHSCT correlated with improved 2-year PFS (65% [highest quartile] vs 45% [lowest quartile]; P = .02) and OS (89% [highest quartile] vs 65% [lowest quartile]; P = .01). Higher CD4⁺ central memory (CM) cell counts post-AHSCT were associated with improved 2-year OS (95% [upper quartile] vs 47% [lowest quartile]; P = .0003) but not PFS. The higher $\gamma\delta$ T-cell and CD4⁺ CM-cell count associations were primarily observed in MRD-negative patients post-AHSCT and in patients not receiving maintenance therapy. This proof-of-concept study demonstrates that IP before and after AHSCT can be of complementary prognostic value for depth of response. Maintenance therapy seems to overcome negative IP. IP and MRD should be measured in clinical trials of maintenance therapy with novel agents post-AHSCT for MM to confirm their utility for prognosis and management.

Introduction

Multiple myeloma (MM) is an incurable disease that is often treated with induction therapy and autologous hematopoietic stem cell transplantation (AHSCT), followed by consolidation and/or maintenance therapy.¹ The goal of initial treatment is to induce a response and prolong the time to disease progression and the need for re-treatment. Because most MM patients will eventually experience disease progression, new strategies must be developed to prolong response and delay time to disease progression. Identifying those patients who have prolonged responses to initial therapy and their clinical characteristics may facilitate the understanding of MM biology and the development of novel strategies to prolong control of this disease.

Submitted 1 February 2017; accepted 12 May 2017. DOI 10.1182/ bloodadvances.2017005447.

Presented at the 55th annual meeting of the American Society of Hematology, New Orleans, LA, 7-10 December 2013, and at the 58th annual meeting of the American Society of Hematology, San Diego, CA, 3-6 December 2016.

The full-text version of this article contains a data supplement. $\ensuremath{\mathbb{C}}$ 2017 by The American Society of Hematology

The immune system is an area of interest for understanding control of MM and other malignancies. Immune cell populations have been profiled before, during, or after therapy to identify immune profiles that are associated with improved outcome. Diagnostic factors associated with improved progression-free survival (PFS) and/or overall survival (OS) include elevated peripheral blood (PB) CD4⁺ count,^2 PB absolute lymphocyte count (ALC) ${>}3000$ cells per $\mu\text{L,}^3$ PB ALC \geq 1400 cells per μ L⁴ higher PB CD4⁺ and CD19⁺ cell count,^{5,6} and higher PB total CD4⁺, CD4⁺ naive, and CD19⁺ cell counts.⁷ After initial therapy, improved PFS and/or OS were seen with PB ALC >800 cells per μL^8 and higher PB CD4⁺, CD4⁺ naive, and CD19⁺ cell counts.⁷ Day +15 post-AHSCT ALC recovery (PB >500 lymphocytes per μ L) correlates with improved PFS and OS.⁹ A higher autograft ALC infused is associated with early ALC recovery. improved OS, and improved time to disease progression.¹⁰ Another study examined T cells (CD3⁺/CD8⁺ or CD3⁺/CD4⁺), natural killer (NK) cells (CD3⁻/CD56⁺), and B cells (CD19⁺) and found that increased PB NK cells on day 30 post-AHSCT were associated with improved PFS but not OS.11 When comparing 20 symptomatic MM patients who had survived >10 years from diagnosis with agematched MM patients who were <10 years from diagnosis, the patients who had survived >10 years had increased proliferative cytotoxic T-cell clones, decreased regulatory T cells (Tregs), and increased proinflammatory Th17 cells.12

Earlier studies did not examine detailed PB subsets before and after AHSCT. We hypothesized that a comprehensive immune profiling (IP) of PB T-cell, NK-cell, B-cell, and dendritic cell (DC) subpopulations would identify immune cell phenotypes associated with prolonged PFS and OS after AHSCT. Examining IP after AHSCT would facilitate our understanding of immune reconstitution post-AHSCT and its correlation with outcome. Developing strategies to enhance selected populations after AHSCT could improve outcomes for MM patients.

Methods

Patient population

This is a retrospective cohort study of 101 consecutive adult (older than age 18 years) MM patients who received a planned single AHSCT at Roswell Park Cancer Institute from August 2007 to January 2014. This study was reviewed and approved by the RPCI institutional review board and was conducted in accordance with the Declaration of Helsinki. Grafts consisted of PB hematopoietic stem cells mobilized with granulocyte colony-stimulating factor (G-CSF) (n = 23), G-CSF plus plerixafor (n = 77), or G-CSF plus plerixafor followed by cyclophosphamide plus G-CSF remobilization (n = 1). Patients underwent apheresis for a minimum of 2 days, regardless of cell dose collected on the first day, to reach a target CD34⁺ cell dose of 4 to 8×10^6 /kg. Extra cells were cryopreserved for potential future use. The minimum CD34⁺ cell dose infused was 2×10^6 /kg. All patients received a high-dose regimen of melphalan in a single dose of 200 mg/m² (n = 85) or, if comorbidities were present, 120 mg/m² (n = 16).

Immune profiling panels

Comprehensive IP was performed on fresh PB samples at a median of 17 days before AHSCT (n = 101) and at a median of 99 days (n = 80) after AHSCT. Table 1 defines the IP panels. Eighty patients had an immunophenotyping assessment for abnormal plasma cells (minimal residual disease [MRD]) performed on bone marrow

Table 1. Immunophenotyping panels

Immune cell phenotype	Epitopes tested
T cells	
CD3 ⁺ total	CD3 ⁺
CD4 ⁺ total	CD4 ⁺
CD8 ⁺ total	CD8 ⁺
T-cell subsets	
CD3 ⁺ CD4 ⁺	CD3 ⁺ CD4 ⁺
CD4 ⁺ CD8 ⁺ double positive	CD3 ⁺ CD4 ⁺ CD8 ⁺
CD4 ⁻ CD8 ⁻ double negative	CD3 ⁺ CD4 ⁻ CD8 ⁻
CD4 ⁺ naive	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CD45RO ⁻ CD27 ⁺
CD4 ⁺ central memory	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CD45RO ⁺ CD27 ⁺
CD4 ⁺ effector memory	CD3 ⁺ CD4 ⁺ CD45RA ⁻ CD45RO ⁺ CD27 ⁻
CD4 ⁺ effector	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CD45RO ⁻ CD27 ⁻
CD4 ⁺ recent thymic emigrants	CD3 ⁺ CD4 ⁺ CD45RA ⁺ CD31 ⁺ CD45RO ⁻
CD4 ⁻ recent thymic emigrants	CD3 ⁺ CD4 ⁻ CD45RA ⁺ CD31 ⁺ CD45RO ⁻
Tregs bright (CD4 ⁺)	CD3 ⁺ CD4 ⁺ CD25 (br)
Tregs dim (CD4 ⁺)	CD3 ⁺ CD4 ⁺ CD25 ⁺ CD127 (d)
Tregs DR ⁺ (CD4 ⁺)	CD3 $^+$ CD4 $^+$ CD25 $^+$ CD127 (d)HLADr $^+$
Tregs dim (CD4⁻)	CD3 ⁺ CD4 ⁻ CD25 ⁺ CD127 (d)
Tregs DR ⁻ (CD4 ⁻)	CD3 ⁺ CD4 ⁻ CD25 ⁺ CD127 ⁻ HLADr ⁻
CD3 ⁺ CD8 ⁺	CD3 ⁺ CD8 ⁺
CD8 ⁺ naive	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CD45RO ⁻ CD27 ⁺
CD8 ⁺ primed (effector)	CD3 ⁺ CD8 ⁺ CD45RA ⁺ CD45RO ⁻ CD27 ⁻
CD8 ⁺ CM	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CD45RO ⁺ CD27 ⁺
CD8 ⁺ effector memory	CD3 ⁺ CD8 ⁺ CD45RA ⁻ CD45RO ⁺ CD27 ⁻
γδ T cells	$CD3^+ \ \gamma \delta^+$
B cells	
CD19 ⁺ total	CD19 ⁺
CD20 ⁺ total	CD20 ⁺
CD19 ⁺ naive	CD19 ⁺ CD27 ⁻
Naive (Bm 1)	CD19 ⁺ CD38 ⁻ lgD ⁺ CD27 ⁻ CD20 ^{+/-}
Naive (Bm 2)	CD19 ⁺ CD38 ⁺ lgD ⁺ CD27 ⁻ CD20 ^{+/-}
CD19 ⁺ memory	CD19 ⁺ CD27 ⁺
Memory pre-switch	CD19 ⁺ CD38 ^{+/-} lgD ⁺ CD27 ⁺ CD20 ^{+/-}
Memory post-switch	CD19 ⁺ CD38 ^{+/-} lgD ⁻ CD27 ⁺ CD20 ^{+/-}
NK cells	
Total NK cells	CD56 ⁺ CD16 ⁺
	CD16/56 ⁺ $\gamma\delta^{+\prime-}$ CD8 ⁻ CD3 ⁺ CD4 ⁺
	$\text{CD16/56}^+ \ \gamma \delta^{+\prime -} \ \text{CD8}^+ \ \text{CD3}^+ \ \text{CD4}^-$
DCs	
Myeloid CD11c ⁺	$\rm HLADr^+CD123^{+/-}\ Dump^-\ CD11c^+$
Plasmacytoid CD123 ⁺	HLADr ⁺ CD123 ⁺ Dump ⁻ CD11c ⁻

Bm, B mature; br, bright; d, dim; DR, antigen D-related.

samples around day +100 post-AHSCT, regardless of disease response (complete response [CR] vs not in CR). Briefly, by using standard flow cytometry immunophenotyping techniques, 3 tubes of 4 fluorochromes per tube were tested for the expression of CD38, CD138, CD45, CD56, CD19, CD117, CD28, and cytoplasmic κ and

Table 2. Patient characteristics

Characteristic	No.	%	Median	Range
Total no. of patients	101			
Age, years			60	28-75
Female sex	55	54		
Myeloma subtype				
Serum				
lgG к	40	40		
lgG λ	16	16		
IgA к	14	14		
IgA λ	12	12		
lgM к	2	2		
lgD к	2	2		
IgD λ	1	1		
Light chain (urine)				
кonly	6	6		
λonly	7	7		
Biclonal (IgG, IgA, κ)	1	1		
Nonsecretory	0	0		
ISS at diagnosis				
1	34	34		
II	29	29		
Ш	27	27		
Missing	11	11		
Durie-Salmon staging at diagnosis				
1	20	20		
II	14	14		
Ш	67	66		
Lines of therapy pre-AHSCT				
1	44	44		
2	35	35		
3	15	15		
>3	7	7		
Pre-AHSCT treatment				
PI/IMiD	71	71		
PI	16	16		
IMiD	12	12		
PI/IMiD/other	1	1		
Other	1	1		
Mobilization regimen				
G-CSF	23	23		
G-CSF + plerixafor	77	76		
G-CSF + plerixafor, then cyclophosphamide + G-CSF remobilization	1	1		
KPS pre-AHSCT				
70	20	19		
80	52	51		
90	29	29		
Time from diagnosis to AHSCT months			10.2	05-621

Table 2. (continued)

Characteristic	No.	%	Median	Range
CD34 dose infused, 10 ⁶ /kg			3.12	1.7-9.93
TNC dose infused, 10 ⁸ /kg			4.83	1.8-44.14

ISS, International Staging System; KPS, Karnofsky performance status; PI, proteasome inhibitor (only); TNC, total nucleated cells.

 $\lambda;$ the majority of samples (>75%) had 250 000 to 2 million events acquired.

Statistical analysis

Univariable analyses of patient and clinical characteristics were conducted by using the Pearson χ^2 test or Fisher's exact text for categorical variables and Wilcoxon 2-sample test or Kruskal-Wallis 1way test for continuous variables, as appropriate. OS was calculated from date of AHSCT to the date of death as a result of any cause; patients were censored if they were alive at last follow-up. PFS time was calculated from date of AHSCT to date of first disease progression/ relapse or death as a result of any cause; patients were censored at last follow-up in the absence of disease progression/relapse. Cell marker categories were defined as ${>}25\%,\,25\%$ to 75%, and ${<}75\%$ of the absolute cell count for each cell type. The middle group was included if it was significantly differentiated from the high and low groups. If the middle group was not significantly differentiated, it was combined with the upper guartile. Kaplan-Meier survival curves were constructed; significance was tested by using the log-rank statistic. The following patient characteristics were tested for association with PFS and OS and were not statistically significant: Karnofsky performance status, race, plerixafor use, CD34⁺ cell dose infused, number of pre-AHSCT lines of therapy, remission status at AHSCT, ALC recovery by day +15, any infection between day 0 and day +100 post-AHSCT, lenalidomidecontaining regimen pre-AHSCT, bortezomib-containing regimen pre-AHSCT, thalidomide-containing regimen pre-AHSCT, body mass index, AHSCT regimen, bisphosphonates pre-AHSCT, and 25-hydroxy vitamin D level pre-AHSCT. Age at AHSCT was the only patient-, disease-, or treatment-related variable that was associated with OS or PFS in the univariable analysis. Therefore, multivariable Cox proportional hazards models were used to estimate the hazard ratio of OS or PFS, adjusting only for age at AHSCT, which was significant in the univariable analysis. Multiple comparisons were considered in the setting of a small sample size, with P < .01 set as the threshold for statistical significance. All statistical analyses were performed by using SAS V9.4 (SAS Institute, Cary, NC).

Results

The characteristics of 101 patients undergoing a single AHSCT are provided in Table 2. The following responses were seen preand post-AHSCT: for patients in CR (n = 16) pre-AHSCT, all remained in CR at day 100 post-AHSCT. For patients with a very good partial response (VGPR; n = 39) pre-AHSCT, 20 (51%) attained a CR, 11 (28%) remained in VGPR, and 8 (21%) were less than VGPR but did not fulfill the criteria for progressive disease. For patients with less than a VGPR (or partial response or better) (n = 43) pre-AHSCT, 13 (30%) attained a CR, 8 (19%) attained a VGPR, and 22 (51%) remained at less than VGPR but did not fulfill the criteria for progressive disease. All patients survived to day +100.



Figure 1. Elevated pre-AHSCT absolute total CD19⁺ B-cell count is significantly associated with improved PFS and OS. For all patients pre-AHSCT, patients with absolute total CD19⁺ B-cell counts in the highest quartile had improved PFS (P = .01) and OS (P = .0003) compared those in the middle and lowest quartiles.

Clinical characteristics and correlation with outcomes

Univariable analysis was performed to evaluate correlation between clinical characteristics and PFS/OS. Patients in CR or stringent CR (sCR) before AHSCT did not have significantly improved PFS (P = .15) or OS (P = .07) when compared with those not in CR or sCR. There was no correlation between age (younger than vs older than age 60 years) and PFS (2-year PFS, 70% vs 61%; P = .1), but there was an improved OS for patients younger than age 60 years at the time of AHSCT (2-year OS, 93% vs 77%; P = .004). We found no PFS or OS association with bisphosphonate use, normal serum immunoglobulin (Ig) levels (IgG, IgA, IgM), pre-AHSCT CD34⁺ dose infused ($< 4 \times 10^{6}$, $4-6 \times 10^6$, and $>6 \times 10^6$ cells per kg), vitamin D deficiency pre-AHSCT, Karnofsky performance status, sex, or type of induction therapy (immunomodulatory drug [IMiD] and/or proteasome inhibitor-containing regimen). No IP subset was associated with Ig levels (IgG, IgA, IgM) tested pre-AHSCT or at day 100 post-AHSCT. No IP subpopulations at day +100 post-AHSCT were associated with attaining or maintaining a CR or sCR at day +100 post-AHSCT. Prior exposure to lenalidomide, bortezomib, or thalidomide as single agents or in combination as part of induction or the most recent salvage regimen before AHSCT was not associated with any particular IP before AHSCT or at day +100 post-AHSCT.

ALC recovery by day +15 following AHSCT: correlation with posttransplant outcomes

Day +15 ALC recovery post-AHSCT was not significantly associated with PFS or OS (supplemental Figure 1A-B). The 2-year PFS was 71% (95% CI, 58% to 83%) for early ALC recovery vs 56% (95% CI, 40% to 72%) for late ALC recovery (P = .25). The 2-year OS was 89% (95% CI, 80% to 98%) for early ALC recovery and 76% (95% CI, 61% to 92%) for late ALC recovery (P = .14). After adjusting for multiple comparisons, there were no significant associations between early ALC recovery and day +100 post-AHSCT immune cell subpopulations (data not shown).

Pre-AHSCT PB immune cell populations: association with PFS/OS/MRD

An elevated pre-AHSCT total PB CD19⁺ B-cell count was significantly associated with improved 2-year PFS (53% for the lowest quartile [0% to 24%], 59% for middle quartiles [25% to 74%], and 83% for the highest quartile [75% to 100%]; note that percentages used here to define lowest, middle, and highest quartiles apply throughout, including the figure legends, unless otherwise stated; P = .01) (Figure 1A) and OS (63% for the lowest, 90% for middle, and 93% for the highest quartile; P = .0003) (Figure 1B). After adjustment for age, CD19⁺ B-cell count remained a significant predictor of PFS and OS. This association was observed in patients whose bone marrow had detectable MRD (MRD-positive) by flow cytometry before AHSCT (n = 49) (supplemental Figure 2C-D). There was no association of pre-AHSCT total PB CD19⁺ B-cell count with PFS or OS for those patients whose bone marrow did not have detectable MRD (MRD-negative) (n = 47) (supplemental Figure 2A-B). Improved outcomes were associated with elevated pre-AHSCT CD19⁺ B-cell count most significantly in those patients who did not receive post-AHSCT maintenance therapy (n = 29) (supplemental Figure 3A-B). For those patients who received post-AHSCT maintenance therapy (n = 71), elevated pre-AHSCT CD19⁺ B-cell count was significantly associated with improved OS but not PFS (supplemental Figure 3C-D). Higher PB total CD20⁺, naive, and memory B-cell counts were the only other immune subpopulations associated with a significantly improved 2-year PFS and OS (Table 3).

				Before Al	ISCT				Da	y +100 aftei	' AHSCT		
Marker	Percentile	2-y PFS (%)	95% CI	٩	2-y OS (%)	95% CI	٩	2-y PFS (%)	95% CI	٩	2-y OS (%)	95% CI	٩
CD3 ⁺ total	<25	56	35-77		72	49-94		64	43-86		74	49-98	
	25-75	65	51-79	NS	85	74-95	NS	60	44-77	NS	84	71-97	NS
	>75	72	54-90		94	84-105		62	39-85		88	71-104	
CD4 ⁺ total	<25	47	26-68		53	27-79		75	56-94		69	41-96	
	25-75	69	55-83	NS	92	85-100	.04	49	32-66	SN	86	74-98	NS
	>75	72	54-90		95	85-105		72	50-94		87	70-104	
CD8 ⁺ total	<25	64	44-85		83	68-98		60	38-81		81	62-101	
	25-75	63	49-77	NS	82	70-95	NS	64	47-80	SN	84	71-97	NS
	>75	68	49-86		06	76-104		59	33-84		80	58-102	
$CD3^+CD4^+$	<25	47	26-68		53	27-79		70	50-90		65	38-92	
	25-75	69	55-83	NS	92	85-100	.04	52	35-69	NS	88	77-99	NS
	>75	72	54-90		95	85-105		72	50-94		87	70-104	
CD4 ⁺ CD8 ⁺ double positive	<25	51	32-71		76	57-95		75	55-94		85	65-105	
	25-75	64	49-79	.04	84	72-96	NS	51	33-68	SN	79	64-93	NS
	>75	77	60-93		92	82-103		67	45-89		87	71-104	
CD4 ⁻ CD8 ⁻ double negative	<25	50	29-72		67	43-91		41	17-65		82	62-101	
	25-75	67	53-81	NS	92	84-100	NS	60	42-78	.05	81	66-97	NS
	>75	72	54-90		84	70-98		80	62-98		84	67-101	
CD4 ⁺ naive	<25	60	39-81		59	29-90		75	56-94		80	62-98	
	25-75	65	51-78	NS	88	78-97	NS	61	44-78	NS	77	60-94	NS
	>75	69	49-89		91	78-103		53	30-75		94	84-105	
CD4 ⁺ central memory	<25	48	26-69		65	42-88		49	26-71		47	21-73	
	25-75	66	52-80	NS	89	79-98	NS	67	51-84	NS	100	100-100	.001
	>75	80	65-96		63	81-106		61	38-84		85	66-104	
CD4 ⁺ effector memory	<25	42	19-65		79	66-09		65	43-86		71	49-93	
	25-75	71	58-84	.01	84	73-95	NS	61	44-78	NS	82	67-97	NS
	>75	72	54-90		06	76-104		57	32-83		95	85-105	
CD4 ⁺ recent thymic emigrants	<25	67	48-86		59	33-86		63	41-85		64	36-92	
	25-75	56	41-71	NS	06	81-98	NS	69	54-85	NS	84	71-97	NS
	>75	80	65-96		92	81-103		49	25-73		63	81-106	
CD4 ⁻ recent thymic emigrants	<25	64	45-83		73	50-95		66	43-89		77	51-103	
	25-75	66	52-81	NS	85	73-96	.03	61	45-78	NS	87	75-99	NS
	>75	62	42-82		92	81-103		56	32-80		76	55-97	
Tregs bright (CD4 ⁺)	<25	61	41-82		77	59-95		55	33-77		77	57-97	
	25-75	64	50-79	NS	88	77-98	NS	53	34-72	NS	85	73-98	NS
	>75	72	55-90		84	68-101		80	62-98		87	70-104	

Downloaded from http://ashpublications.net/bloodadvances/article-pdf/1/15/1056/878494/advances005447.pdf by guest on 01 June 2024

Table 3. Two-year PFS and OS

				Before Al	ISCT				ă	ay +100 after	r AHSCT		
Marker	Percentile	2-y PFS (%)	95% CI	Ρ	2-y OS (%)	95% CI	Ρ	2-y PFS (%)	95% CI	٩	2-y OS (%)	95% CI	٩
Tregs dim (CD4 ⁺)	<25	46	25-68		61	40-83		59	37-81		66	43-89	
	25-75	68	54-83	NS	96	90-101	.04	54	37-72	NS	87	74-99	NS
	>75	77	60-93		85	69-101		77	57-98		92	78-107	
Tregs DR ⁺ (CD4 ⁺)	<25	53	30-75		86	70-101		47	24-70		89	74-104	
	25-75	62	48-76	NS	81	68-93	NS	60	43-76	NS	76	61-91	NS
	>75	85	71-98		06	76-104		83	64-101		89	68-109	
Tregs dim (CD4 ⁻)	<25	49	26-72		85	68-101		60	38-82		77	56-98	
	25-75	72	59-85	NS	81	69-93	NS	62	45-79	NS	84	71-97	NS
	>75	64	45-83		06	76-103		63	40-85		86	68-104	
Tregs DR ⁻ (CD4 ⁻)	<25	50	28-72		85	68-101		65	43-86		74	51-98	
	25-75	68	54-82	NS	78	65-91	NS	58	41-75	NS	81	67-95	NS
	>75	71	53-90		95	86-104		68	46-89		93	79-106	
CD3 + CD8 +	<25	61	41-81		74	53-95		59	37-81		74	49-98	
	25-75	66	52-80	NS	86	75-97	NS	64	48-80	NS	87	76-99	NS
	>75	67	47-86		06	76-104		58	33-84		80	58-102	
CD8 ⁺ naive	<25	66	47-86		76	55-96		80	62-98		80	62-98	
	25-75	59	44-74	NS	83	71-95	.03	54	36-71	NS	78	61-94	NS
	>75	74	56-92		94	84-105		54	30-78		94	82-106	
CD8 ⁺ primed (effector)	<25	57	36-78		76	54-99		70	50-90		80	58-102	
	25-75	68	54-81	NS	85	74-96	NS	63	47-80	NS	78	62-94	NS
	>75	66	47-86		88	75-101		46	21-71		89	75-103	
CD8 ⁺ central memory	<25	41	18-63		76	57-96		53	28-78		06	76-103	
	25-75	74	61-87	NS	88	78-98	NS	50	33-68	.003	74	58-90	NS
	>75	69	51-87		84	68-101		89	75-103		91	74-108	
CD8 ⁺ effector memory	<25	58	35-80		87	72-101		56	32-80		06	77-103	
	25-75	69	55-82	NS	84	72-95	NS	58	41-75	NS	79	64-94	NS
	>75	63	43-83		85	69-101		72	50-93		80	57-102	
γδ T cells	<25	52	31-73		70	48-91		45	23-67		65	42-88	
	25-75	62	47-77	NS	87	77-98	NS	59	40-77	.05	06	79-101	.04
	>75	80	65-96		92	81-103		78	59-97		87	71-104	
CD19 ⁺ total	<25	53	33-74		63	40-86		64	42-85		69	46-92	
	25-75	59	44-75	01	06	81-98	.0003	66	50-82	NS	86	73-99	NS
	>75	83	69-98		93	81-106		50	22-77		06	77-103	
CD20 ⁺ total	<25	39	17-61		63	40-86		63	41-85		68	43-92	
	25-75	69	55-83	.001	06	81-98	.01	66	50-82	NS	87	74-99	NS
	>75	78	61-95		94	82-106		50	22-77		06	77-103	
NS, not significant.													

Table 3. (continued)

				Before	AHSCT				ŏ	ay +100 a	fter AHSCT		
Marker	Percentile	2-y PFS (%)	95% CI	٩	2-y OS (%)	95% CI	Р	2-y PFS (%)	95% CI	٩	2-y OS (%)	95% CI	٩
CD19 ⁺ naive	<25	53	33-74		71	50-91		63	41-85		68	43-92	
	25-75	62	48-77	.01	86	76-97	.002	65	49-80	SN	87	74-99	NS
	>75	78	60-95		63	81-106		52	24-81		89	76-103	
CD19 ⁺ naive (Bm 2)	<25	53	33-74		67	46-87		63	41-85		68	43-92	
	25-75	60	45-75	.01	85	73-97	.0002	67	51-83	SN	87	74-99	NS
	>75	82	66-98		÷			49	21-76		89	76-103	
CD19 ⁺ memory	<25	51	31-71		65	43-87		56	33-80		82	62-101	
	25-75	62	47-77	.05	89	79-98	.01	68	52-84	NS	82	67-97	NS
	>75	84	69-98		94	82-106		59	37-81		83	64-101	
CD19 ⁺ memory pre-switch	<25	58	38-78		73	52-94		54	30-78		82	63-101	
	25-75	63	48-77	NS	89	80-98	NS	67	51-83	NS	88	76-99	NS
	>75	75	57-93		84	66-102		64	42-85		72	47-97	
CD10 ⁺ memory post-switch	<25	43	22-65		61	38-84		80	58-102		94	84-105	
	25-75	69	55-83	NS	91	82-100	.01	57	40-74	SN	76	60-92	NS
	>75	76	59-93		94	83-105		54	31-76		85	69-101	
Total NK cells	<25	63	40-86		85	69-101		60	35-85		78	59-97	
	25-75	59	45-73	NS	79	66-92	NS	65	49-80	NS	82	68-97	NS
	>75	76	59-93		94	83-105		49	23-75		06	77-103	
CD16/56 ⁺ $\gamma \delta^{+/-}$ CD8 ⁻ CD3 ⁺ CD4 ⁺	<25	62	42-82		77	54-100		54	32-76		72	47-97	
	25-75	61	46-75	NS	81	69-93	NS	60	43-77	SN	88	27-99	NS
	>75	75	57-92		95	85-105		72	50-94		80	60-101	
CD16/56 ⁺ $\gamma \delta^{+/-}$ CD8 ⁺ CD3 ⁺ CD4 ⁻	<25	75	58-92		88	74-101		69	48-90		75	46-104	
	25-75	61	46-75	NS	82	70-95	NS	67	51-82	.05	91	80-101	NS
	>75	64	45-83		87	73-101		43	17-69		68	44-92	
Myeloid CD11c ⁺	<25	62	43-82		68	46-90		54	32-76		75	53-98	
	25-75	62	47-77	NS	87	78-97	NS	59	43-76	SN	81	67-95	NS
	>75	76	58-93		94	82-106		74	52-97		95	85-105	
Plasmacytoid CD123 ⁺	<25	68	47-88		70	43-96		56	32-79		89	74-104	
	25-75	56	42-70	NS	85	74-95	NS	59	42-75	SN	76	61-92	NS
	>75	85	71-98		89	75-104		74	54-94		06	77-103	

Table 3. (continued)

NS, not significant.







Figure 3. Elevated day + 100 post-AHSCT absolute CD4⁺ CM cell count is significantly associated with improved OS but not PFS. (A-B) For all patients at day + 100 post-AHSCT, those with absolute CD4⁺ CM T-cell counts in the top 3 quartiles combined had improved OS (P = .0003) but not PFS (P = .2) compared with those in the lowest quartile.

Day 100 post-AHSCT immune cell populations: association with PFS/OS/MRD and maintenance therapy

IP at day 100 post-AHSCT and the association with PFS and OS is shown in Table 3. Higher PB γδ T-cell counts correlated with improved 2-year PFS: 45% for the lowest and 65% for the highest quartile (P = .02) and OS: 65% for the lowest and 89% for the highest quartile (P = .01) (Figure 2A-B). After adjustment by age, γδ T-cell count remained a significant predictor of PFS and OS. Unlike the pre-AHSCT PB CD19⁺ B-cell population, this association was observed in those patients with MRD-negative bone marrow tests at day 100 post-AHSCT (n = 60) (Figure 2C-D) and not in those patients with MRD-positive bone marrow tests (n = 15) (Figure 2E-F). Day +100 AHSCT PB CD4⁺ central memory (CM) cell counts were significantly associated with improved OS: 47% for the lowest and 95% for the highest quartile (P = .0003) (Figure 3B), but there was no association with PFS (Figure 3A). After adjustment for age, CD4⁺ CM T-cell count remained a significant predictor of OS. This association was observed in those patients with MRD-negative bone marrow tests at day 100 post-AHSCT (n = 60) (supplemental Figure 4A-B) and was not observed in patients with MRD-positive bone marrow tests (n = 15) (supplemental Figure 4C-D).

Improved outcomes were associated with elevated $\gamma\delta$ T cells (supplemental Figure 5A-B) and elevated CD4⁺ CM T cells (supplemental Figure 6A-B), most significantly in patients who did not receive any post-AHSCT maintenance therapy (n = 22); improved outcomes were not observed in patients who received post-

AHSCT maintenance therapy (n = 58) (supplemental Figures 5C-D and 6C-D).

Discussion

This was a proof-of-concept study that highlighted the feasibility of performing IP in MM patients pre- and post-AHSCT and the potential prognostic significance of IP in these patients. It also illustrates the benefit of IP and the importance of incorporating it into future clinical trials. Our modern cohort of patients had improved responses to novel combination therapies with median OS with lenalidomide maintenance of up to 10 years. Early surrogate end points are necessary for clinical trial development.

This report did not find a correlation with ALC recovery (a surrogate for immune recovery) and PFS or OS, unlike previous studies.^{3,4,8} This may be a result of the higher ALCs infused in the stem cell products in this study when compared with other studies. Other factors that may account for this difference were found in previous reports that included a greater proportion of patients with refractory disease, more patients receiving bone marrow grafts (20% vs 0%), and induction regimens without IMiDs and proteasome inhibitors and no plerixafor use.⁹ In comparison with other studies, this analysis did not demonstrate any significance between number of Tregs and PFS or OS. The studies that found that decreased Tregs were associated with long-term disease control performed IP in the bone marrow.^{13,14} In contrast, our study performed IP in the PB, likely accounting for the difference in findings. We plan to include bone marrow IP in future studies.

Figure 2. Elevated day +100 post-AHSCT absolute $\gamma\delta$ T-cell count is significantly correlated with improved PFS and OS in all patients and in those who are **MRD-negative.** (A-B) For all patients at day +100 post-AHSCT, those with absolute $\gamma\delta$ T-cell counts in the top 3 quartiles combined had improved PFS (P = .02) and OS (P = .01) compared with those in the lowest quartile. (C-D) For patients who had no detectable MRD (n = 60) by flow cytometry at day +100 post-AHSCT elevated absolute $\gamma\delta$ T-cell count was significantly correlated with improved PFS (P = .02) and OS (P = .02). (E-F) For patients who had detectable MRD (n = 15) by flow cytometry at day +100 post-AHSCT, there was no significant correlation with elevated absolute $\gamma\delta$ T-cell counts and PFS (P = .8) and OS (P = .5).

This analysis centered on comprehensive IP in the PB of MM patients undergoing AHSCT to determine whether more defined immune populations were associated with outcome. Higher CD19⁺ B-cell populations before AHSCT were associated with improved PFS and OS. This may represent a return to B-cell immune functionality and would be a surrogate for robust immune reconstitution after antimyeloma induction therapy. These findings are evocative of the observation that higher levels of CD19⁺ B cells at diagnosis predict for response and longer event-free survival and OS.⁶ Patients whose bone marrow was MRD-positive with low PB B-cell numbers had inferior outcomes, whereas patients who were MRD-negative were not impacted by the level of PB B cells. This would suggest that myeloma cytoreduction during induction is important for predicting outcome, but those with MRD benefit from an enhanced immune profile. Improved outcomes were significantly associated with elevated pre-AHSCT CD19⁺ B-cell counts for patients who did not receive any post-AHSCT maintenance therapy. This reinforces the concept that immune competence, as manifested by improved B-cell counts, is correlated with improved outcomes.

This is the first report demonstrating that higher PB $\gamma\delta$ T-cell numbers at day +100 post-AHSCT are associated with improved PFS and OS. $\gamma\delta$ T cells respond to infections and tumor antigens as components of innate and adaptive immunity. ¹⁵ The pleiotropic functions of $\gamma\delta$ T cells include antigen presentation to, co-stimulation of, and triggering of $\alpha\beta$ T-cell proliferation and differentiation, eliciting antitumor cells by CD8⁺ and CD4⁺ T cells as well as being directly cytotoxic. ^{16,17} Other $\gamma\delta$ T-cell functions include macrophage recruitment, DC maturation, cytokine and chemokine secretion, and regulation of B-cell function. ¹⁶ CD4⁺ CM cells have been associated with lymph node homing, DC stimulation, and differentiation into CD4⁺ effector cells. ¹⁸

Improved PFS and OS with elevated $\gamma\delta$ T cells (and OS in the case of CD4⁺ CM cells) were seen in patients who were MRD-negative at day 100 post-AHSCT and not in those who were MRD-positive. This would imply that a higher tumor cell burden would not be controlled only by a favorable IP. Indeed a favorable IP exerted a beneficial effect primarily in patients who did not receive maintenance therapy, although the applicability of this finding is limited given the small number of patients who did not receive maintenance therapy. Thus maintenance therapy seems to overcome negative IP, and we need to further understand the pleiotropic effects of lenalidomide on immune function.^{19,20} Because the majority of patients received lenalidomide, it is not possible to determine whether the same effect would be seen with bortezomib.

Bisphosphonates, including zoledronate and pamidronate, can stimulate $\gamma\delta$ T-cell proliferation resulting in cytotoxic activity against myeloma cell lines and decreased survival of malignant plasma cells from MM patients' bone marrow.^{21,22} Lenalidomide enhances $\gamma\delta$ T-cell proliferation and activity against the malignant B cells.^{23} Many MM patients receive bisphosphonates and/or lenalidomide as part of initial therapy. In our patient population, because of the combined use of both drugs, we could not differentiate whether there was an effect of lenalidomide

or zoledronate on $\gamma\delta$ T-cell subpopulations and outcome before and after AHSCT. Bisphosphonate and lenalidomide administration are standard treatments after transplantation. Thus, future investigation should focus on how elevated $\gamma\delta$ T-cell levels are attained after transplantation and whether this elevation leads to improved outcome.

This study was limited by retrospective design and a relatively small MM patient population; however, the patient population was representative of a standard transplantation center. The lack of association between induction regimen and IP likely reflects patient and treatment heterogeneity. The detailed IP is an advantage for determining the effect of lymphocyte populations on outcome. Although this study focused on cellular immune profiles, it remains a critical question whether any major cytokines and chemokines from these immune cells contribute to the patients' outcome. Although previous studies have addressed the significance of a few cytokines and chemokines in MM,^{24,25} it will require a separate study to define how soluble factors from these major types of effector cells (eg, $\gamma\delta$ T cells, CD3⁺/CD4⁺/CD8⁺ T cells, and NK cells) affect the 2-year PFS and OS in patients. This has implications for emerging immunotherapies such as daratumumab, which has been shown to have profound immune effects,²⁶ and elotuzumab, which has synergistic action with lenalidomide.²⁷

It is well established that IMiDs have immunomodulatory effects as well.²⁸ Robust recovery of specific immune cell subpopulations may represent a protective effect for the MM patient after AHSCT. The role of prolonged therapy to maintain response will be the subject of future studies. Understanding how immune subpopulations trigger and regulate the immune response to tumor may enable long-term control of MM.

Acknowledgments

This work was partially supported by National Institutes of Health National Cancer Institute grant P30CA016056 involving the use of the Roswell Park Cancer Institute Flow and Imaging Cytometry Shared Resource.

Authorship

Contribution: P.L.M., P.K.W., and T.H. designed the research; C.M.H., P.L.M., P.K.W., A.F., P.M., B.L.S.M., B.P., and T.H. performed research and collected data; C.M.H., Y.Z., P.K.W., and T.H. analyzed data; C.M.H., P.L.M., Y.Z., P.K.W., J.D.T, G.L.C., S.A.H., X.C., B.P., and T.H. interpreted results; C.M.H., P.L.M., Y.Z., P.K.W., P.M., G.L.C., S.A.H., S.R.B., X.C., B.P., and T.H. wrote the paper; and all authors gave final approval of the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: P.L.M., 0000-0002-9577-3879.

Correspondence: Christine M. Ho, Department of Medicine, Blood and Marrow Transplantation, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263; e-mail: christine.ho@ roswellpark.org.

References

- 1. McCarthy PL, Hahn T. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantationeligible multiple myeloma patients. *Hematology Am Soc Hematol Educ Program.* 2013;2013:496-503.
- San Miguel JF, González M, Gascón A, et al; Cooperative Group for the Study of Monoclonal Gammopathies. Lymphoid subsets and prognostic factors in multiple myeloma. Br J Haematol. 1992;80(3):305-309.

- 4. Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *Br J Haematol.* 2008;141(6):792-798.
- 5. Kay NE, Leong T, Bone N, et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. *Br J Haematol.* 1998; 100(3):459-463.
- 6. Kay NE, Leong T, Kyle RA, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. *Blood.* 1997;90(1):340-345.
- 7. Kay NE, Leong TL, Bone N, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. *Blood*. 2001;98(1):23-28.
- 8. Narwani V, Gabriel J, Boyd K, Chevassut T. Absolute lymphocyte count at day 29 of treatment is a powerful predictor of outcome in multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2015;15(4):222-226.
- Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. *Blood*. 2001;98(3):579-585.
- Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2004; 33(3):291-298.
- 11. Rueff J, Medinger M, Heim D, Passweg J, Stern M. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. *Biol Blood Marrow Transplant.* 2014;20(6):896-899.
- 12. Bryant C, Suen H, Brown R, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. *Blood Cancer J.* 2013;3(9):e148.
- Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. *Haematologica*. 2013;98(1):79-86.
- 14. Favaloro J, Brown R, Aklilu E, et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. *Leuk Lymphoma*. 2014;55(5):1090-1098.
- 15. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol. 2006;126(1):25-31.
- 16. Wu YL, Ding YP, Tanaka Y, et al. γδ T cells and their potential for immunotherapy. Int J Biol Sci. 2014;10(2):119-135.
- 17. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309(5732):264-268.
- Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999;401(6754):708-712.
- 19. Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: Current status and future potential. *Am J Hematol.* 2012;87(12):1089-1095.
- 20. Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: Mechanisms of action and clinical experience. Drugs. 2017;77(5):505-520.
- 21. Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. *Cytotherapy*. 2012;14(9):1110-1118.
- 22. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. *Blood.* 2000;96(2):384-392.
- Gaidarov S, Corral LG, Gleizer E, et al. Lenalidomide enhances anti-tumor effect of γδ T cells against mantle cell lymphoma [abstract]. Blood. 2008; 112(11). Abstract 2616.
- 24. Kline M, Donovan K, Wellik L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. *Leuk Res.* 2007;31(5):591-598.
- 25. Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol. 1993;92(1):27-31.
- 26. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood.* 2016;128(3):384-394.
- 27. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. *J Clin Oncol.* 2012;30(16):1953-1959.
- 28. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.